Fortress Biotech Q3 EPS $(0.94) Beats $(3.21) Estimate, Sales $34.75M Up From $16.53M YoY
Portfolio Pulse from Benzinga Newsdesk
Fortress Biotech (NASDAQ:FBIO) reported Q3 EPS of $(0.94), surpassing the $(3.21) estimate, marking a 70.72% beat and a 21.67% improvement from last year's $(1.20) per share. Sales rose to $34.75M, a 110.26% increase from $16.53M YoY.
November 14, 2023 | 10:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Fortress Biotech reported a significant earnings beat and a substantial increase in sales compared to the same quarter last year.
The substantial beat on both earnings and revenue estimates is likely to be viewed positively by investors, potentially leading to a short-term increase in stock price as the market reacts to the strong financial performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100